Insiders Akero Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
23.5 ^USD	-1.47%		+6.05%	+0.64%

06-11	Wolfe Research Initiates Coverage on Akero Therapeutics With Outperform Rating, $40 Price Target	MT
06-11	Akero Therapeutics, Inc. Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH	CI

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer	04-30	CI
Akero Therapeutics Insider Sold Shares Worth $732,727, According to a Recent SEC Filing	03-07	MT
Akero Therapeutics Insider Sold Shares Worth $2,465,063, According to a Recent SEC Filing	03-07	MT
Akero Therapeutics Insider Bought Shares Worth $1,982,940, According to a Recent SEC Filing	12-12	MT
Akero Therapeutics Insider Sold Shares Worth $1,197,827, According to a Recent SEC Filing	23-10-05	MT
Akero Therapeutics Insider Sold Shares Worth $1,244,248, According to a Recent SEC Filing	23-09-19	MT
Insider Buy: Akero Therapeutics	23-08-10	MT
Insider Sell: Akero Therapeutics	23-08-03	MT
Insider Buy: Akero Therapeutics	23-08-02	MT
Insider Sell: Akero Therapeutics	23-07-07	MT
Insider Sell: Akero Therapeutics	23-06-26	MT
Insider Sell: Akero Therapeutics	23-06-21	MT
Insider Sell: Akero Therapeutics	23-06-21	MT
Insider Sell: Akero Therapeutics	23-06-21	MT
Insider Sell: Akero Therapeutics	23-06-06	MT
Insider Sell: Akero Therapeutics	23-05-04	MT
Insider Sell: Akero Therapeutics	23-03-03	MT
Insider Sell: Akero Therapeutics	23-02-03	MT
Insider Sell: Akero Therapeutics	23-01-18	MT
Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy	23-01-10	CI

No results for this search